LXEO Earnings & Financial Statements
Lexeo Therapeutics, Inc. Common Stock
$2.80
-$0.25(-8.06%)
30
Overall
50
Value
18
Tech
23
Quality
Market Cap
$265.01M
Volume
887.46K
52W Range
$2.98 - $10.99
Target Price
$20.30
LXEO earnings and financial statements: Lexeo Therapeutics, Inc. Common Stock's income statement, balance sheet and cash flow statement, annual and quarterly.
LXEO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $654.0K | $1.66M |
| Operating income | -$109.26M | -$105.77M | -$68.51M | -$60.51M | -$50.64M |
| EBITDA | -$97.79M | -$96.19M | -$64.35M | -$59.07M | -$50.61M |
| Net income | -$99.96M | -$98.33M | -$66.39M | -$59.28M | -$50.62M |
| EPS (diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 | $-32.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $268.69M | $146.94M | $139.81M | $97.08M | $136.87M |
| Total liabilities | $22.02M | $30.10M | $26.27M | $25.00M | $7.45M |
| Shareholders’ equity | $246.67M | $116.84M | $113.53M | $72.08M | $129.41M |
| Cash and equivalents | $63.00M | $35.01M | $121.47M | $77.33M | $135.86M |
| Long-term debt | $5.21M | $7.25M | $9.03M | $9.00M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$98.56M | -$81.15M | -$59.50M | -$54.56M | -$44.18M |
| Capital expenditure | -$397.0K | -$481.0K | -$165.0K | - | - |
| Free cash flow | -$98.96M | -$81.63M | -$59.66M | -$55.23M | -$44.37M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LXEO | $2.80 | -8.1% | 887.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Lexeo Therapeutics, Inc. Common Stock Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW